Nanobiotix (NANO) Guggenheim Inaugural Global Healthcare Innovation Conference summary

Technology platform overview

• Focus on nanophysics-based, first-in-class products with strong IP protection and minimal competition.

• Main oncology platform centers on NBTXR3, a radio enhancer for cancer treatment.

Mechanism of action and clinical rationale

• NBTXR3 is a one-time injectable nanoparticle drug that amplifies the effect of radiation within tumors.

• Enhances tumor cell kill and triggers an immune response, potentially improving local control and survival.

• Addresses the limitation of radiation by increasing tumor dose without added toxicity to healthy tissue.

Lead indication and clinical development

• Prioritizing head and neck cancer, especially frail elderly patients ineligible for cisplatin, due to high radiation use and unmet need.

• Phase I/II data showed 82% response rate and 63% complete response, with median overall survival of 23.1 months.

• Ongoing Phase III trial (500 patients) compares radiation ± cetuximab vs. same plus NBTXR3; primary endpoint is PFS, with readout expected H1 2026.